Prognosis of Acute Promyelocytic Leukemia Treatment Over Time
Author Information
Author(s): Emilia Scalzulli, Alessandro Costa, Ida Carmosino, Paolo Musiu, Maria Laura Bisegna, Maria Stefania De Propris, Claudia Ielo, Daniela Diverio, Clara Minotti, Saveria Capria, Roberto Latagliata, Maurizio Martelli, Massimo Breccia
Primary Institution: Sapienza University of Rome
Hypothesis
What are the prognostic factors and outcomes of different treatment protocols for patients with acute promyelocytic leukemia (APL) over time?
Conclusion
The study found that treatment protocols significantly affect survival rates in APL patients, with newer protocols showing improved outcomes.
Supporting Evidence
- 97.2% of patients received induction therapy.
- Complete response rates varied significantly by treatment protocol.
- 5-year overall survival rates were 90.5% for low-risk, 78.9% for intermediate-risk, and 66.1% for high-risk patients.
Takeaway
This study looked at 220 people with a type of blood cancer called APL and found that the way they were treated made a big difference in how long they lived.
Methodology
A retrospective analysis of 220 APL patients treated from 1993 to 2022, collecting data on treatment responses and survival rates.
Potential Biases
Potential biases may arise from the retrospective nature of the study and the lack of randomization.
Limitations
The study is retrospective and lacks randomization, which may affect the reliability of the findings.
Participant Demographics
The mean age of participants was 50 years, with 49% male.
Statistical Information
P-Value
p=0.044
Confidence Interval
95% CI, 78.1–83.5 for 3-year OS; 95% CI, 76.4–81.8 for 5-year OS
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website